Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

Ramalingam, Suresh S.; Dahlberg, Suzanne E.; Langer, Corey J.; Gray, Robert J.; Belani, Chandra P.; Brahmer, Julie R.; Sandler, Alan; Schiller, Joan H.; Johnson, David H.

doi:10.1200/jco.2007.13.1144

Cited by 319 publications

(208 citation statements)

References 28 publications

Supporting

Mentioning

194

Contrasting

Unclassified

Order By: Relevance

“…(7) This underlying mechanism may be responsible for the more severe hematologic toxicities of cytotoxic chemotherapy regimens, for example cyclophosphamidedoxorubicin in breast cancer and bevacizumabpaclitaxel-carboplatin in NSCLC. (13,14) However, an association between age and severity was not documented in these studies, and another study in NSCLC cases with paclitaxel-carboplatin chemotherapy also yielded similar results. (15) The hematologic toxicities occurring in EOC patients after having received paclitaxelcarboplatin chemotherapy are influenced by several factors, i.e.…”

Section: Discussionmentioning

confidence: 85%

Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients

Charles

Dewayani

Winarno

et al. 2016

UnivMed

View full text Add to dashboard Cite

BACKGROUNDEpithelial ovarian cancer (EOC) is one of the most common cancers diagnosed in Indonesian women. A combination of paclitaxel and carboplatin is used to treat EOC as standard chemotherapy which is known to have hematologic toxicities. This study aimed to investigate the effect of combined paclitaxel-carboplatin chemotherapy on hematologic status in EOC patients managed at Dr. Hasan Sadikin General Hospital, Bandung, West Java.

show abstract

Section: Discussionmentioning

confidence: 85%

Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients

Charles

Dewayani

Winarno

et al. 2016

UnivMed

View full text Add to dashboard Cite

show abstract

“…Grade III-IV adverse events were significantly more frequent in the elderly subjects compared with the younger subjects (87 vs. 61%) (12). Another retrospective analysis was performed on 304 elderly patients aged ≥65 years, out of a total of 1,430 patients enrolled in the AVAiL study, comparing the cisplatin/gemcitabine regimen alone or in combination with two different bevacizumab doses.…”

Section: Activity Of Bevacizumabmentioning

confidence: 99%

“…The studies on the activity of these novel therapies in the elderly patient with NSCLC are few (8,9), comprising a more fragmented and less numerous casuistry than the experience accumulated in the younger patient (10,11). The majority of significant retrospective data are obtained by subgroup analysis of elderly patients from the large studies performed without age restriction (12)(13)(14). To date, a lower contribution has been provided from prospective studies specifically designed to evaluate the efficacy and safety of molecular-targeted drugs in elderly patients with NSCLC (15)(16)(17)(18)(19)(20)(21).…”

Section: Introductionmentioning

confidence: 99%

Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

Abstract. Lung cancer is the most common cause of cancer-related mortality in men and women. Non-small cell lung cancer (NSCLC) represents close to 90% of all lung cancers. When diagnosed, >50% of patients are >65 years old. Through an improved understanding of the molecular mechanisms involved in lung oncogenesis, molecular-targeted approaches have become an essential element for the treatment of patients with NSCLC. As the toxicity profiles of the techniques are definitely more favorable compared with chemotherapy, they are particularly attractive for use in elderly patients, who are potentially more susceptible to the toxicity of systemic oncological therapies. However, studies on the activity of molecular-targeted agents in this aged patient setting are much more limited compared with those in their younger counterparts. In the present review, the literature on molecular-targeted therapy for elderly patients with advanced NSCLC is discussed. It is concluded that bevacizumab should be reserved only for highly select elderly patients with advanced NSCLC when the clinician deems it useful in the face of acceptable toxicities. In elderly patients with advanced epidermal growth factor receptor mutation-positive NSCLC, erlotinib and gefitinib appear to repeat the same favorable performance as that documented on a larger scale in the overall population of patients with activating mutations. A good toxicity profile is also confirmed for active molecules on different pathways, such as crizotinib. IntroductionThe 'elderly' patient with lung cancer treated with cytotoxic chemotherapy has been the subject of several studies that have assumed international importance due to sample size, methodological rigor and impact on clinical practice. Confirmed by evidence-based medicine, these important trials have led to the definition of therapeutic standards validated in this patient subset: The ELVIS study showed the superiority of vinorelbine over placebo (1); the MILES study showed a similar effectiveness between single-agent vinorelbine or gemcitabine, and single-agent efficacy over the combination of vinorelbine plus gemcitabine (2); the MILES 2P study showed better survival for cisplatin plus gemcitabine compared with cisplatin plus vinorelbine (3); the IFCT-0501 study showed survival benefits with carboplatin plus weekly paclitaxel compared with vinorelbine or gemcitabine monotherapy (4); another study showed improved survival with platinum-based adjuvant chemotherapy (5); and in a phase II trial involving elderly patients with advanced-stage small cell lung cancer, the weekly regimen of gemcitabine and docetaxel demonstrated no advantage over standard therapy (6).The last decade of research in this field has witnessed the emergence of molecular-targeted therapies as an essential element for the treatment of patients with non-small cell lung cancer (NSCLC) (7). The studies on the activity of these novel therapies in the elderly patient with NSCLC are few (8,9), comprising a more fragmented and less numerous casuistry tha...

show abstract

“…Initial phase II trial results have shown some efficacy with these agents in advanced NSCLC. 99,100 The results of ongoing phase III trials are awaited.…”

Section: Angiogenesis and Vascular Endothelial Growth Factormentioning

confidence: 99%

Advances in the prevention and treatment of lung cancer

Sethi²

2011

J R Coll Physicians Edinb

View full text Add to dashboard Cite

Lung cancer remains the most common fatal malignancy in the Western world. Survival rates have only improved modestly over the past three decades and new approaches are urgently required. It is clear that a concerted effort to reduce cigarette smoking is required. However, about 10% of patients with lung cancer are never smokers, indicating genetic or other predisposition. Lung cancer screening programmes are being trialled to target high-risk populations. Genetic strategies will provide new methods for screening and predicting response to treatment. Current therapy for lung cancer has reached a plateau and novel agents have shown modest clinical efficacy. Understanding the mechanisms by which chronic inflammatory disorders such as chronic obstructive pulmonary disease contribute to lung cancer development will help to identify new biological targets and biomarkers of early disease. This review focuses on recent advances in lung cancer prevention and treatment.

show abstract

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

Abstract: In elderly NSCLC patients, PCB was associated with a higher degree of toxicity, but no obvious improvement in survival compared with PC. Data from this unplanned, retrospective analysis justify prospective evaluation of the therapeutic index of PCB regimen in elderly patients.

Cited by 319 publications

References 28 publications

Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients

Paclitaxel-carboplatin chemotherapy induced hematologic toxicities among epithelial ovarian cancer patients

Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer

Advances in the prevention and treatment of lung cancer

Contact Info

Product

Resources

About